Denali Net Borrowings vs Capital Expenditures Analysis

DNLI Stock

USD 20.92 0.53 2.47%

Denali Therapeutics financial indicator trend analysis is much more than just examining Denali Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Denali Therapeutics is a good investment. Please check the relationship between Denali Therapeutics Net Borrowings and its Capital Expenditures accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.

Net Borrowings vs Capital Expenditures

Net Borrowings vs Capital Expenditures Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Denali Therapeutics Net Borrowings account and Capital Expenditures. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Denali Therapeutics' Net Borrowings and Capital Expenditures is -0.27. Overlapping area represents the amount of variation of Net Borrowings that can explain the historical movement of Capital Expenditures in the same time period over historical financial statements of Denali Therapeutics, assuming nothing else is changed. The correlation between historical values of Denali Therapeutics' Net Borrowings and Capital Expenditures is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Borrowings of Denali Therapeutics are associated (or correlated) with its Capital Expenditures. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Expenditures has no effect on the direction of Net Borrowings i.e., Denali Therapeutics' Net Borrowings and Capital Expenditures go up and down completely randomly.

Correlation Coefficient

-0.27

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Net Borrowings

The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.

Capital Expenditures

Capital Expenditures are funds used by Denali Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Denali Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Most indicators from Denali Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Denali Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.The current Selling General Administrative is estimated to decrease to about 54.3 M. The current Tax Provision is estimated to decrease to -6,300

	2021	2022	2023	2024 (projected)
Interest Income	4.6M	14.8M	51.5M	54.1M
Net Interest Income	4.6M	14.8M	45.0M	47.3M

Interest Income Net Interest Income

Denali Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Preferred Stock Total Equity	Total Current Assets	Common Stock
Total Assets		0.91	0.75	0.99	0.49	0.96	0.89	-0.75	-0.79	0.43	0.85	0.64	0.7	0.64	0.98	0.65	0.92	0.5	0.93	0.93	0.94	0.9	0.79	0.77	0.98	0.66
Other Current Liab	0.91		0.77	0.91	0.21	0.91	0.88	-0.53	-0.89	0.57	0.67	0.49	0.76	0.53	0.91	0.59	0.87	0.28	0.89	0.9	0.96	0.79	0.84	0.66	0.91	0.59
Total Current Liabilities	0.75	0.77		0.69	-0.04	0.67	0.67	-0.41	-0.67	0.31	0.52	0.72	0.61	0.86	0.67	0.4	0.69	0.04	0.68	0.81	0.74	0.83	0.54	0.47	0.68	0.43
Total Stockholder Equity	0.99	0.91	0.69		0.46	0.98	0.88	-0.71	-0.82	0.5	0.82	0.61	0.74	0.58	0.97	0.71	0.93	0.45	0.94	0.92	0.95	0.82	0.81	0.83	0.98	0.72
Other Liab	0.49	0.21	-0.04	0.46		0.44	0.38	-0.76	0.01	-0.25	0.72	0.09	-0.09	0.07	0.54	0.22	0.36	0.97	0.29	0.27	0.29	0.51	0.2	0.33	0.53	0.22
Net Tangible Assets	0.96	0.91	0.67	0.98	0.44		0.87	-0.69	-0.81	0.51	0.79	0.56	0.74	0.56	0.96	0.57	0.94	0.45	0.94	0.93	0.95	0.8	0.8	0.76	0.96	0.57
Property Plant And Equipment Net	0.89	0.88	0.67	0.88	0.38	0.87		-0.5	-0.81	0.48	0.67	0.57	0.67	0.53	0.87	0.64	0.94	0.45	0.88	0.9	0.91	0.8	0.89	0.77	0.87	0.64
Net Debt	-0.75	-0.53	-0.41	-0.71	-0.76	-0.69	-0.5		0.26	0.03	-0.97	-0.42	-0.16	-0.37	-0.75	-0.37	-0.49	-0.73	-0.55	-0.5	-0.51	-0.74	-0.33	-0.51	-0.74	-0.38
Retained Earnings	-0.79	-0.89	-0.67	-0.82	0.01	-0.81	-0.81	0.26		-0.83	-0.46	-0.45	-0.95	-0.41	-0.78	-0.59	-0.84	-0.04	-0.93	-0.85	-0.9	-0.59	-0.94	-0.62	-0.78	-0.6
Accounts Payable	0.43	0.57	0.31	0.5	-0.25	0.51	0.48	0.03	-0.83		0.17	0.34	0.89	-0.03	0.4	0.41	0.53	-0.22	0.72	0.54	0.58	0.19	0.8	0.35	0.41	0.4
Cash	0.85	0.67	0.52	0.82	0.72	0.79	0.67	-0.97	-0.46	0.17		0.5	0.35	0.4	0.85	0.46	0.64	0.72	0.72	0.64	0.65	0.83	0.55	0.58	0.85	0.47
Non Current Assets Total	0.64	0.49	0.72	0.61	0.09	0.56	0.57	-0.42	-0.45	0.34	0.5		0.53	0.67	0.47	0.5	0.63	0.1	0.6	0.72	0.56	0.64	0.46	0.58	0.47	0.51
Non Currrent Assets Other	0.7	0.76	0.61	0.74	-0.09	0.74	0.67	-0.16	-0.95	0.89	0.35	0.53		0.39	0.66	0.52	0.79	-0.07	0.88	0.81	0.82	0.49	0.85	0.54	0.67	0.54
Other Assets	0.64	0.53	0.86	0.58	0.07	0.56	0.53	-0.37	-0.41	-0.03	0.4	0.67	0.39		0.56	0.35	0.62	0.08	0.48	0.71	0.59	0.71	0.26	0.51	0.56	0.38
Cash And Short Term Investments	0.98	0.91	0.67	0.97	0.54	0.96	0.87	-0.75	-0.78	0.4	0.85	0.47	0.66	0.56		0.62	0.89	0.55	0.9	0.88	0.93	0.86	0.78	0.74	1.0	0.63
Common Stock Total Equity	0.65	0.59	0.4	0.71	0.22	0.57	0.64	-0.37	-0.59	0.41	0.46	0.5	0.52	0.35	0.62		0.6	0.12	0.61	0.58	0.66	0.41	0.6	0.89	0.62	1.0
Common Stock Shares Outstanding	0.92	0.87	0.69	0.93	0.36	0.94	0.94	-0.49	-0.84	0.53	0.64	0.63	0.79	0.62	0.89	0.6		0.4	0.92	0.97	0.96	0.79	0.85	0.77	0.9	0.61
Non Current Liabilities Total	0.5	0.28	0.04	0.45	0.97	0.45	0.45	-0.73	-0.04	-0.22	0.72	0.1	-0.07	0.08	0.55	0.12	0.4		0.31	0.32	0.33	0.59	0.26	0.24	0.55	0.12
Capital Surpluse	0.93	0.89	0.68	0.94	0.29	0.94	0.88	-0.55	-0.93	0.72	0.72	0.6	0.88	0.48	0.9	0.61	0.92	0.31		0.92	0.93	0.76	0.93	0.71	0.91	0.62
Other Current Assets	0.93	0.9	0.81	0.92	0.27	0.93	0.9	-0.5	-0.85	0.54	0.64	0.72	0.81	0.71	0.88	0.58	0.97	0.32	0.92		0.96	0.84	0.82	0.72	0.88	0.59
Other Stockholder Equity	0.94	0.96	0.74	0.95	0.29	0.95	0.91	-0.51	-0.9	0.58	0.65	0.56	0.82	0.59	0.93	0.66	0.96	0.33	0.93	0.96		0.78	0.86	0.76	0.93	0.67
Total Liab	0.9	0.79	0.83	0.82	0.51	0.8	0.8	-0.74	-0.59	0.19	0.83	0.64	0.49	0.71	0.86	0.41	0.79	0.59	0.76	0.84	0.78		0.62	0.5	0.86	0.42
Property Plant And Equipment Gross	0.79	0.84	0.54	0.81	0.2	0.8	0.89	-0.33	-0.94	0.8	0.55	0.46	0.85	0.26	0.78	0.6	0.85	0.26	0.93	0.82	0.86	0.62		0.63	0.79	0.61
Preferred Stock Total Equity	0.77	0.66	0.47	0.83	0.33	0.76	0.77	-0.51	-0.62	0.35	0.58	0.58	0.54	0.51	0.74	0.89	0.77	0.24	0.71	0.72	0.76	0.5	0.63		0.74	0.89
Total Current Assets	0.98	0.91	0.68	0.98	0.53	0.96	0.87	-0.74	-0.78	0.41	0.85	0.47	0.67	0.56	1.0	0.62	0.9	0.55	0.91	0.88	0.93	0.86	0.79	0.74		0.63
Common Stock	0.66	0.59	0.43	0.72	0.22	0.57	0.64	-0.38	-0.6	0.4	0.47	0.51	0.54	0.38	0.63	1.0	0.61	0.12	0.62	0.59	0.67	0.42	0.61	0.89	0.63

Click cells to compare fundamentals

Denali Therapeutics Account Relationship Matchups

Denali Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	553.2M	1.6B	1.4B	1.5B	1.2B	932.8M
Other Current Liab	20.4M	42.5M	47.7M	63.8M	61.2M	31.3M
Total Current Liabilities	45.3M	71.7M	378.2M	363.9M	78.0M	121.8M
Total Stockholder Equity	394.9M	1.2B	962.3M	1.0B	1.0B	712.9M
Other Liab	44.1M	317.9M	5.1M	858K	986.7K	937.4K
Net Tangible Assets	394.9M	1.2B	962.3M	1.0B	1.2B	612.3M
Property Plant And Equipment Net	80.7M	73.5M	69.6M	74.5M	71.6M	52.4M
Net Debt	(10.6M)	(443.0M)	(234.9M)	(157.7M)	(74.9M)	(78.6M)
Retained Earnings	(425.6M)	(354.4M)	(645.0M)	(971.0M)	(1.1B)	(1.1B)
Accounts Payable	2.6M	1.1M	4.8M	2.8M	9.5M	10.0M
Cash	79.4M	507.1M	293.5M	218.0M	127.1M	194.5M
Non Current Assets Total	123.2M	108.6M	506.9M	87.9M	89.8M	154.9M
Non Currrent Assets Other	2.7M	2.5M	11.9M	11.9M	18.1M	19.1M
Other Assets	2.7M	2.5M	11.9M	13.4M	1.0	0.95
Cash And Short Term Investments	415.4M	1.5B	865.4M	1.3B	1.0B	757.9M
Common Stock Shares Outstanding	95.6M	112.7M	121.5M	125.5M	137.4M	86.7M
Liabilities And Stockholders Equity	553.2M	1.6B	1.4B	1.5B	1.2B	932.8M
Non Current Liabilities Total	113.0M	382.1M	63.6M	53.9M	45.0M	42.7M
Capital Surpluse	774.2M	818.8M	1.5B	1.6B	1.8B	1.9B
Other Current Assets	14.7M	20.3M	30.6M	26.8M	26.2M	17.6M
Other Stockholder Equity	818.8M	1.5B	1.6B	2.0B	2.1B	1.1B
Total Liab	158.3M	453.7M	441.9M	417.8M	123.0M	220.0M
Property Plant And Equipment Gross	80.7M	73.5M	69.6M	74.5M	117.6M	123.5M
Total Current Assets	430.0M	1.5B	897.2M	1.4B	1.1B	778.0M
Accumulated Other Comprehensive Income	350K	(245K)	(2.5M)	(6.9M)	643K	675.2K
Common Stock	1.3M	1.5M	1.5M	1.7M	1.7M	1.6M
Property Plant Equipment	80.7M	40.8M	69.6M	74.5M	85.7M	44.6M
Short Term Investments	335.9M	962.6M	571.9M	1.1B	907.4M	633.8M
Long Term Investments	61.3M	147.9M	39.9M	32.7M	425.4M	0.0
Non Current Liabilities Other	467K	471K	379K	382.1M	435.9K	414.1K
Net Invested Capital	394.9M	1.2B	962.3M	1.0B	1.0B	879.0M
Net Working Capital	384.7M	1.4B	519.0M	1.0B	986.2M	811.7M
Current Deferred Revenue	18.7M	23.5M	320.3M	290.1M	(46.9M)	(44.6M)
Capital Stock	1.3M	1.5M	1.5M	1.7M	1.7M	1.7M
Short Term Debt	3.7M	4.7M	5.5M	7.3M	7.3M	6.3M

Currently Active Assets on Macroaxis

C	Citigroup
GM	General Motors
F	Ford Motor
GM	General Motors
V	Visa Class A

When determining whether Denali Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Denali Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Denali Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Denali Therapeutics Stock:

How To Invest In Denali

Details

Is Denali Stock a good investment?

Details

What is Denali Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.

You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.76)

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.24)

Return On Equity

(0.35)

The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Denali Net Borrowings vs Capital Expenditures Analysis

Net Borrowings vs Capital Expenditures

Net Borrowings vs Capital Expenditures Correlation Analysis

Correlation Coefficient

Net Borrowings

Capital Expenditures

Denali Therapeutics fundamental ratios Correlations

Denali Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Denali Therapeutics fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Common Stock Total Equity
Total Stockholder Equity	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.98	Total Assets
Total Current Assets	+ 0.98	Total Assets
Net Tangible Assets	+ 0.98	Total Stockholder Equity

Cash	- 0.97	Net Debt
Non Currrent Assets Other	- 0.95	Retained Earnings
Property Plant And Equipment Gross	- 0.94	Retained Earnings
Capital Surpluse	- 0.93	Retained Earnings
Other Stockholder Equity	- 0.9	Retained Earnings
Retained Earnings	- 0.89	Other Current Liab